Covidien Spin-Out Mallinckrodt Makes First Move With $1.3B Cadence Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
In its first big deal since spinning out last July, the Irish-based specialty pharma is gaining a hospital-based sales and marketing team, a high-margin recently launched pain product and NOLs to gain tax advantages.